Telo Genomics (3D0A) Stock Overview
A molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
3D0A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.017 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.001 |
| Beta | -0.35 |
| 1 Month Change | 73.68% |
| 3 Month Change | -2.94% |
| 1 Year Change | -77.40% |
| 3 Year Change | -92.34% |
| 5 Year Change | -88.78% |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3D0A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 120.0% | 7.0% | -1.0% |
| 1Y | -77.4% | -27.2% | 12.0% |
Return vs Industry: 3D0A underperformed the German Biotechs industry which returned -27.2% over the past year.
Return vs Market: 3D0A underperformed the German Market which returned 12% over the past year.
Price Volatility
| 3D0A volatility | |
|---|---|
| 3D0A Average Weekly Movement | 231.4% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3D0A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3D0A's weekly volatility has increased from 142% to 231% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company’s TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients.
Telo Genomics Corp. Fundamentals Summary
| 3D0A fundamental statistics | |
|---|---|
| Market cap | €4.65m |
| Earnings (TTM) | -€1.68m |
| Revenue (TTM) | n/a |
Is 3D0A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3D0A income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.72m |
| Earnings | -CA$2.72m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3D0A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 02:06 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telo Genomics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.